About this item:

434 Views | 0 Downloads

Author Notes:

Author correspondence: Jack L Arbiser, Department of Dermatology, Emory University School of Medicine, WMB 5309, 101 Woodruff Circle, Atlanta, GA 30322. Phone: 404-727-5063; Fax: 404-727-0923; Email: jarbise@emory.edu


Research Funding:

JLA was supported by the grant RO1 AR47901and P30 AR42687 Emory Skin Disease Research Core Center Grant from the National Institutes of Health, a Veterans Administration Hospital Merit Award.

Application of Angiogenesis to Clinical Dermatology


Journal Title:

Advances in Dermatology


Volume 24


, Pages 89-103

Type of Work:

Article | Post-print: After Peer Review


As defined in this chapter by Drs. Fried and Arbiser, angiogenesis is “the process by which normal and pathologic tissue derives a blood supply”. Increasingly, angiogenesis has been shown to play critical roles in inflammatory as well as neoplastic processes. Understanding the molecular basis of angiogenesis, including the homing of bone marrow endothelial cell precursors to newly established sites of angiogenesis, has given us many potential therapeutic targets related to formation or maintenance of blood vessels. The recent approval of an anti-VEGF antibody, bevacizumab, for cancer therapy is one such example and many more appear to be on their way. Dr. Jack Arbiser, the senior author of this review, has been a leader in elucidating the molecular basis of angiogenesis (e.g., the role of reactive oxygen species) as well as pioneer in using new and established drugs (e.g., gentian violet) to block angiogenesis in a variety of settings, including the treatment of hemangiomas, that have relevance in dermatology.

Copyright information:

© 2008 Elsevier

Export to EndNote